2 research outputs found
Lysine pathway metabolites and the risk of type 2 diabetes and cardiovascular disease in the PREDIMED study: results from two case-cohort studies
Background: The pandemic of cardiovascular disease (CVD) and type 2 diabetes (T2D) requires the identifcation
of new predictor biomarkers. Biomarkers potentially modifable with lifestyle changes deserve a special interest. Our
aims were to analyze: (a) The associations of lysine, 2-aminoadipic acid (2-AAA) or pipecolic acid with the risk of T2D
or CVD in the PREDIMED trial; (b) the efect of the dietary intervention on 1-year changes in these metabolites, and (c)
whether the Mediterranean diet (MedDiet) interventions can modify the efects of these metabolites on CVD or T2D
risk.
Methods: Two unstratifed case-cohort studies nested within the PREDIMED trial were used. For CVD analyses, we
selected 696 non-cases and 221 incident CVD cases; for T2D, we included 610 non-cases and 243 type 2 diabetes
incident cases. Metabolites were quantifed using liquid chromatography–tandem mass spectrometry, at baseline and
after 1-year of intervention.
Results: In weighted Cox regression models, we found that baseline lysine (HR+1 SD increase=1.26; 95% CI 1.06–1.51)
and 2-AAA (HR+1 SD increase=1.28; 95% CI 1.05–1.55) were both associated with a higher risk of T2D, but not with CVD.
A signifcant interaction (p=0.032) between baseline lysine and T2D on the risk of CVD was observed: subjects with
prevalent T2D and high levels of lysine exhibited the highest risk of CVD. The intervention with MedDiet did not have
a signifcant efect on 1-year changes of the metabolites.
Conclusions: Our results provide an independent prospective replication of the association of 2-AAA with future
risk of T2D. We show an association of lysine with subsequent CVD risk, which is apparently diabetes-dependent. No
evidence of efects of MedDiet intervention on lysine, 2-AAA or pipecolic acid changes was found
Lysine pathway metabolites and the risk of type 2 diabetes and cardiovascular disease in the PREDIMED study: results from two case-cohort studies
Background: The pandemic of cardiovascular disease (CVD) and type 2 diabetes (T2D) requires the identifcation
of new predictor biomarkers. Biomarkers potentially modifable with lifestyle changes deserve a special interest. Our
aims were to analyze: (a) The associations of lysine, 2-aminoadipic acid (2-AAA) or pipecolic acid with the risk of T2D
or CVD in the PREDIMED trial; (b) the efect of the dietary intervention on 1-year changes in these metabolites, and (c)
whether the Mediterranean diet (MedDiet) interventions can modify the efects of these metabolites on CVD or T2D
risk.
Methods: Two unstratifed case-cohort studies nested within the PREDIMED trial were used. For CVD analyses, we
selected 696 non-cases and 221 incident CVD cases; for T2D, we included 610 non-cases and 243 type 2 diabetes
incident cases. Metabolites were quantifed using liquid chromatography–tandem mass spectrometry, at baseline and
after 1-year of intervention.
Results: In weighted Cox regression models, we found that baseline lysine (HR+1 SD increase=1.26; 95% CI 1.06–1.51)
and 2-AAA (HR+1 SD increase=1.28; 95% CI 1.05–1.55) were both associated with a higher risk of T2D, but not with CVD.
A signifcant interaction (p=0.032) between baseline lysine and T2D on the risk of CVD was observed: subjects with
prevalent T2D and high levels of lysine exhibited the highest risk of CVD. The intervention with MedDiet did not have
a signifcant efect on 1-year changes of the metabolites.
Conclusions: Our results provide an independent prospective replication of the association of 2-AAA with future
risk of T2D. We show an association of lysine with subsequent CVD risk, which is apparently diabetes-dependent. No
evidence of efects of MedDiet intervention on lysine, 2-AAA or pipecolic acid changes was found